Sign In
Buy SMMT
$15.07
+0.210 (+1.41%)
At Close: Jun 03, 2026
Piper starts Summit Therapeutics with Neutral on high expectations
06:31am, Tuesday, 19'th Aug 2025
Piper Sandler analyst Kelsey Goodwin last night initiated coverage of Summit Therapeutics with a Neutral rating and $21 price target. The firm believes investor expectations for ivonescimab are too hi
3 Fantastic Growth Stocks to Buy in August
06:42am, Sunday, 17'th Aug 2025
We're well into the home stretch of 2025. August is more than halfway over.
Ivonescimab Data from Global Phase III HARMONi Study to be Showcased at Presidential Symposium at WCLC 2025
07:00am, Thursday, 14'th Aug 2025
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that data from the Phase III HARMONi trial featuring the novel, potential f
SMMT Q2 Loss Wider Than Expected, Ivonescimab Studies in Focus
12:46pm, Tuesday, 12'th Aug 2025
Summit Therapeutics posts wider-than-expected second-quarter loss as ivonescimab trials advance in multiple lung cancer settings.
SMMT Investors Have Opportunity to Lead Summit Therapeutics Inc. Securities Fraud Lawsuit with the Schall Law Firm
04:30am, Tuesday, 12'th Aug 2025
LOS ANGELES , Aug. 12, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Summit Therapeutics Inc. ("Summit"
SMMT Investors Have Opportunity to Lead Summit Therapeutics Inc. Securities Fraud Lawsuit with the Schall Law Firm
08:07pm, Monday, 11'th Aug 2025
LOS ANGELES--(BUSINESS WIRE)---- $SMMT--SMMT Investors Have Opportunity to Lead Summit Therapeutics Inc. Securities Fraud Lawsuit with the Schall Law Firm.
Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter Ended June 30, 2025
05:03pm, Monday, 11'th Aug 2025
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on operational progress for the
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
10:00am, Sunday, 27'th Jul 2025
NEW YORK , July 27, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Summit Therapeutics Inc. ("Summit" or the "Company") (NASDAQ: SMMT). Such investors are advi
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
10:00am, Tuesday, 22'nd Jul 2025
NEW YORK , July 22, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Summit Therapeutics Inc. ("Summit" or the "Company") (NASDAQ: SMMT). Such investors are ad
3 Healthcare Stocks to Buy Before They Announce Game-Changing Clinical Trial Results
04:14am, Tuesday, 22'nd Jul 2025
Few things can jolt a pharmaceutical company's shares like positive results from highly anticipated clinical trials. Even so, long-term investors should have a balanced approach to potentially positiv
3 Monster Stocks in the Making to Buy Right Now
12:07am, Monday, 21'st Jul 2025
Where can you find the next monster stocks? Check out the biotech space.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
10:00am, Thursday, 17'th Jul 2025
NEW YORK , July 17, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Summit Therapeutics Inc. ("Summit" or the "Company") (NASDAQ: SMMT). Such investors are advi
SMMT Investors Have Opportunity to Join Summit Therapeutics Inc. Fraud Investigation with the Schall Law Firm
03:00pm, Monday, 14'th Jul 2025
LOS ANGELES--(BUSINESS WIRE)---- $SMMT--SMMT Investors Have Opportunity to Join Summit Therapeutics Inc. Fraud Investigation with the Schall Law Firm.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
10:00am, Saturday, 12'th Jul 2025
NEW YORK , July 12, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Summit Therapeutics Inc. ("Summit" or the "Company") (NASDAQ: SMMT). Such investors are advise
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT
04:07pm, Monday, 07'th Jul 2025
NEW YORK , July 7, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Summit Therapeutics Inc. ("Summit" or the "Company") (NASDAQ: SMMT). Such investors are advis
